Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
(1999) In Neuroscience Letters 273(1). p.5-8- Abstract
- We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1296634
- author
- Andreasen, N ; Minthon, Lennart LU ; Vanmechelen, E ; Vanderstichele, H ; Davidsson, P ; Winblad, B and Blennow, K
- organization
- publishing date
- 1999
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Neuroscience Letters
- volume
- 273
- issue
- 1
- pages
- 5 - 8
- publisher
- Elsevier
- external identifiers
-
- scopus:0032857103
- ISSN
- 0304-3940
- DOI
- 10.1016/S0304-3940(99)00617-5
- language
- English
- LU publication?
- yes
- id
- 6cfde800-2612-4897-98c8-5486614d215a (old id 1296634)
- date added to LUP
- 2016-04-01 11:51:11
- date last changed
- 2022-05-06 18:06:41
@article{6cfde800-2612-4897-98c8-5486614d215a, abstract = {{We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.}}, author = {{Andreasen, N and Minthon, Lennart and Vanmechelen, E and Vanderstichele, H and Davidsson, P and Winblad, B and Blennow, K}}, issn = {{0304-3940}}, language = {{eng}}, number = {{1}}, pages = {{5--8}}, publisher = {{Elsevier}}, series = {{Neuroscience Letters}}, title = {{Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment}}, url = {{http://dx.doi.org/10.1016/S0304-3940(99)00617-5}}, doi = {{10.1016/S0304-3940(99)00617-5}}, volume = {{273}}, year = {{1999}}, }